Free Trial

kneat.com (TSE:KSI) Shares Down 10.4% After Analyst Downgrade

kneat.com logo with Medical background

Key Points

  • kneat.com stock price fell by 10.4% following an analyst downgrade from Raymond James Financial, which lowered the price target from C$7.50 to C$7.00.
  • During mid-day trading, 345,481 shares were exchanged, marking a significant increase of 302% compared to its average session volume.
  • kneat.com specializes in developing software for regulated industries, with its Kneat Gx solution aimed at enhancing product quality and compliance in the life sciences sector.
  • Looking to Export and Analyze kneat.com Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

kneat.com, inc. (TSE:KSI - Get Free Report)'s share price was down 10.4% during mid-day trading on Wednesday after Raymond James Financial lowered their price target on the stock from C$7.50 to C$7.00. Raymond James Financial currently has an outperform rating on the stock. kneat.com traded as low as C$5.17 and last traded at C$5.37. Approximately 345,481 shares changed hands during trading, an increase of 302% from the average daily volume of 85,873 shares. The stock had previously closed at C$5.99.

kneat.com Stock Down 2.0%

The firm has a market cap of C$551.66 million, a P/E ratio of -63.73, a price-to-earnings-growth ratio of 597.67 and a beta of 1.08. The stock's 50 day simple moving average is C$6.03 and its 200 day simple moving average is C$6.26. The company has a debt-to-equity ratio of 85.50, a quick ratio of 1.50 and a current ratio of 1.43.

About kneat.com

(Get Free Report)

kneat.com Inc is in the business of developing and marketing a software application for modelling regulated data-intensive processes for regulated industries, focusing on the life sciences industry. The company has developed Kneat Gx solution which provides management real-time visibility and control and increases product, quality, and compliance.

See Also

Should You Invest $1,000 in kneat.com Right Now?

Before you consider kneat.com, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and kneat.com wasn't on the list.

While kneat.com currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines